Merck Continues Looking For The “Right” Biotech Buying Opportunity
This article was originally published in The Pink Sheet Daily
Speaking at a Goldman Sachs investor conference, CEO Clark discusses Merck’s plans in biotech.
You may also be interested in...
In 2009, Merck is implementing a new business model that fundamentally transforms the company and is crucial to its future, CEO Richard Clark told analysts at a Goldman Sachs health care conference Jan. 7
Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.
Want to know how bad off small biotechs are these days? Investment bankers are so desperate to unload companies, they've taken to calling on corporate development departments with lists of "wounded animals" - those companies with just a few months of cash remaining, according to a business development head at a big pharmaceutical company